公开(公告)号：US20240358866A1

公开(公告)日：2024-10-31

申请号：US18523771

申请日：2023-11-29

申请人： Reiley Pharmaceuticals, Inc.

发明人： B. Michael SILBER ,  Frank KAYSER ,  Mark A. REILEY

IPC分类号： A61K51/04 ,  G01N33/60

CPC分类号： A61K51/0497 ,  A61K51/0446 ,  A61K51/0453 ,  A61K51/0485 ,  G01N33/60 ,  G01N2800/102 ,  G01N2800/2842 ,  G01N2800/52

摘要： Compounds derived from celecoxib, valdecoxib, and indomethacin, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The compounds contain a radioactive agent which permits imaging. The compounds concentrate at sites of increased cyclooxygenase expression, such as areas of increased COX-2 expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections, assessing efficacy of diagnosis and treatment of rheumatoid arthritis, and assessing the need for treatment with opioid drugs.

公开(公告)号：US20180273603A1

公开(公告)日：2018-09-27

申请号：US15844022

申请日：2017-12-15

申请人： Levicept Limited

发明人： Simon WESTBROOK

IPC分类号： C07K14/705

CPC分类号： C07K14/70578 ,  A61K38/00 ,  C07K14/00 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30 ,  G01N2800/28 ,  G01N2800/2807 ,  G01N2800/2842 ,  H05K999/99

摘要： The present invention relates to a p75NTR neurotrophin binding protein (NBP)-Fc fusion protein comprising a p75NTR(NBP) portion and an immunoglobulin portion. In certain embodiments, the p75NTR(NBP)-Fc fusion protein is for use in the treatment of pain and/or a symptom of pain.

公开(公告)号：US09970003B2

公开(公告)日：2018-05-15

申请号：US14912435

申请日：2014-08-11

申请人： OSAKA UNIVERSITY

发明人： Toshihide Yamashita ,  Yasufumi Hayano

IPC分类号： A61K39/395 ,  C07K16/18 ,  C07K16/28 ,  C12N15/113 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/68 ,  A61K39/00

CPC分类号： C12N15/113 ,  A61K39/00 ,  C07K16/18 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q1/68 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/15 ,  G01N33/6872 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2800/2842

摘要： The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.

公开(公告)号：US20180088130A1

公开(公告)日：2018-03-29

申请号：US15609959

申请日：2017-05-31

申请人： Cedars-Sinai Medical Center

发明人： Mark Pimentel ,  Christopher Chang

IPC分类号： G01N33/68 ,  A61K38/17

CPC分类号： G01N33/6887 ,  A61K38/1709 ,  G01N33/564 ,  G01N2333/4703 ,  G01N2333/705 ,  G01N2800/06 ,  G01N2800/065 ,  G01N2800/2842

摘要： Described herein are methods and systems for the detection of anti-vinculin antibodies, for determining a presence or likely presence of a gastrointestinal motility disorder, bladder motility disorder, or fibromyalgia. Further provided are methods of selecting and/or administering a therapy based on the presence or absence of anti-vinculin antibodies.

公开(公告)号：US20170335332A1

公开(公告)日：2017-11-23

申请号：US15660075

申请日：2017-07-26

申请人： Jean VALMIER

发明人： Jean VALMIER

IPC分类号： C12N15/113 ,  C07K16/28 ,  G01N33/50 ,  A61K31/404 ,  C12N15/115 ,  A61K31/553

CPC分类号： C12N15/1138 ,  A61K31/404 ,  A61K31/553 ,  C07K16/28 ,  C12N15/115 ,  C12N2310/14 ,  G01N33/5032 ,  G01N2333/91205 ,  G01N2500/02 ,  G01N2800/2842

摘要： The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.

公开(公告)号：US20170273917A1

公开(公告)日：2017-09-28

申请号：US15511033

申请日：2015-09-10

申请人： Yeda Research and Development Co. Ltd.

发明人： Anthony FUTERMAN ,  Andres David KLEIN

IPC分类号： A61K31/13 ,  G01N33/50 ,  A61K49/00 ,  C12Q1/68

CPC分类号： A61K31/13 ,  A61K9/0019 ,  A61K31/439 ,  A61K49/0004 ,  C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/50 ,  G01N33/5058 ,  G01N2800/28 ,  G01N2800/2842

摘要： The present invention provides pharmaceutical compositions comprising at least one NMDA receptor antagonist for use in treating neuropathic forms of Gaucher Disease (nGD).

公开(公告)号：US20170181987A1

公开(公告)日：2017-06-29

申请号：US15393380

申请日：2016-12-29

申请人： Camilla SVENSSON ,  Lars KLARESKOG ,  Vivianne MALMSTROM ,  Anca CATRINA

发明人： Camilla SVENSSON ,  Lars KLARESKOG ,  Vivianne MALMSTROM ,  Anca CATRINA

IPC分类号： A61K31/18 ,  G06F19/00 ,  G01N33/564 ,  A61K31/4462 ,  G01N33/68

CPC分类号： A61K31/18 ,  A61K31/185 ,  A61K31/341 ,  A61K31/4462 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  G01N33/6869 ,  G01N2333/5421 ,  G01N2800/2842 ,  G01N2800/52 ,  G16H10/20 ,  Y02A90/26

摘要： Pain associated with a contribution of IL-8 and osteoclasts in a subject is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin 8 (IL-8). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.

公开(公告)号：US09642862B2

公开(公告)日：2017-05-09

申请号：US13299232

申请日：2011-11-17

申请人： Hillary D. White

发明人： Hillary D. White

IPC分类号： A61K31/5685 ,  A61K31/568

CPC分类号： A61K31/5685 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/568 ,  A61K45/06 ,  G01N33/5094 ,  G01N33/6896 ,  G01N33/743 ,  G01N2333/4737 ,  G01N2800/2842 ,  G01N2800/52 ,  G01N2800/7095

摘要： The invention relates to a method of reducing chronic inflammatory pain in a human subject with androgen deficiency symptoms comprising transdermally administering a pain-reducing amount of a composition comprising a bioactive androgen to the subject on a daily basis. The invention relates to a method of increasing the pain threshold of a human subject having symptoms of androgen deficiency comprising transdermally administering a composition comprising a pain threshold-increasing amount of a bioactive androgen to the subject with androgen deficiency symptoms on a daily basis. The invention may be used to treat males and females in order to alleviate chronic inflammatory pain or to raise the subject's pain threshold. The invention also relates to increasing the levels of endogenous opioid peptides in a human subject by administering an androgen composition to the subject.

公开(公告)号：US20170097364A1

公开(公告)日：2017-04-06

申请号：US15079503

申请日：2016-03-24

申请人： National University Corporation Hokkaido University ,  Fujirebio Inc. ,  SRL, Inc.

发明人： Hiroshi WAKAO ,  Chie Sugimoto

IPC分类号： G01N33/68 ,  G01N33/569

CPC分类号： G01N33/6896 ,  G01N33/56972 ,  G01N33/6863 ,  G01N33/6872 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70596 ,  G01N2333/7158 ,  G01N2800/2842

摘要： The present invention provides a novel marker for diagnosing fibromyalgia syndrome (FMS). More specifically, the present invention provides a method for diagnosing FMS, comprising measurement of (1) the relative frequency of MAITs to the total T cells in a sample; or (2) the expression level of one or more surface antigens selected from the group consisting of CD4, CD8, CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8β, CD44 and CXCR4 for MAITs in a sample, wherein the sample is a biological sample collected from a human; and a diagnosis kit for FMS, comprising a means for measuring (1) the relative frequency of MAITs to the total T cells in a sample; or (2) the expression level of one or more surface antigens selected from the group consisting of CD4, CD8, CCR4, CCR7, CXCR1, NKp80, CD150, CD107a, CD8β, CD44 and CXCR4 for MAITs in a sample, wherein the sample is a biological sample collected from a human.

公开(公告)号：US09592301B2

公开(公告)日：2017-03-14

申请号：US14704319

申请日：2015-05-05

申请人： Board of Regents of the University of Texas System ,  OTC Biotechnologies, LLC

发明人： Kenneth Michael Hargreaves ,  John Gordon Bruno

IPC分类号： C12N15/115 ,  G01N33/92 ,  A61K47/48

CPC分类号： C12N15/115 ,  A61K31/192 ,  A61K31/56 ,  A61K31/7088 ,  A61K45/06 ,  A61K47/549 ,  A61K47/55 ,  A61K47/60 ,  C12N2310/16 ,  C12N2310/351 ,  C12N2310/3515 ,  C12N2310/3519 ,  C12N2320/30 ,  C12N2320/32 ,  G01N33/5308 ,  G01N33/92 ,  G01N2405/00 ,  G01N2800/2842

摘要： A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

摘要翻译： 用于治疗和/或诊断受试者的疼痛，疼痛，休克和/或炎症状况的来源或类型的方法。 使用治疗有效量的对OLAM具有高亲和力至少部分治疗受试者的疼痛，休克和/或炎性病症的DNA或RNA适配体的方法。 对OLAMs显示出高亲和力的DNA或RNA适配体可以与血浆蛋白结合化合物或药理学活性剂偶联。 一种治疗和/或诊断受试者的疼痛，休克和/或炎性病症的方法可包括使用DNA或者使用DNA来灭活或预防至少一种亚油酸代谢物来治疗某些病症（例如疼痛，休克和/或炎症） 对OLAM显示出高亲和力的RNA适体。